EXACT Sciences Co. (NASDAQ:EXAS) – Svb Leerink issued their Q1 2020 earnings per share (EPS) estimates for EXACT Sciences in a report issued on Wednesday, February 12th. Svb Leerink analyst P. Souda expects that the medical research company will post earnings per share of ($0.67) for the quarter. Svb Leerink also issued estimates for EXACT Sciences’ Q2 2020 earnings at ($0.44) EPS, Q3 2020 earnings at ($0.35) EPS, Q4 2020 earnings at ($0.22) EPS, FY2020 earnings at ($1.68) EPS, Q1 2021 earnings at ($0.17) EPS, Q2 2021 earnings at ($0.16) EPS, Q3 2021 earnings at ($0.10) EPS, Q4 2021 earnings at ($0.09) EPS, FY2021 earnings at ($0.53) EPS and FY2022 earnings at $1.33 EPS.
EXACT Sciences (NASDAQ:EXAS) last announced its earnings results on Tuesday, February 11th. The medical research company reported $0.54 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.91. EXACT Sciences had a negative return on equity of 29.06% and a negative net margin of 29.83%. The firm had revenue of $295.58 million for the quarter, compared to analysts’ expectations of $294.39 million.
Other research analysts have also recently issued research reports about the company. Jefferies Financial Group dropped their price target on EXACT Sciences from $138.00 to $120.00 and set a “buy” rating on the stock in a report on Wednesday, October 30th. Citigroup started coverage on EXACT Sciences in a report on Monday, January 6th. They issued a “buy” rating and a $120.00 price target on the stock. Leerink Swann dropped their price target on EXACT Sciences from $133.00 to $105.00 and set an “outperform” rating on the stock in a report on Wednesday, October 30th. Zacks Investment Research cut EXACT Sciences from a “buy” rating to a “hold” rating and set a $92.00 price target on the stock. in a report on Tuesday, January 21st. Finally, ValuEngine raised EXACT Sciences from a “hold” rating to a “buy” rating in a report on Saturday. One equities research analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $121.00.
NASDAQ EXAS opened at $98.18 on Friday. The stock has a market capitalization of $12.58 billion, a P/E ratio of -57.41 and a beta of 1.36. EXACT Sciences has a 1 year low of $75.35 and a 1 year high of $123.99. The business’s fifty day moving average is $94.13 and its two-hundred day moving average is $97.43. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.63 and a current ratio of 2.75.
In other EXACT Sciences news, insider G Bradley Cole sold 28,016 shares of the business’s stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $80.38, for a total transaction of $2,251,926.08. Following the sale, the insider now directly owns 30,987 shares of the company’s stock, valued at approximately $2,490,735.06. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 2.20% of the stock is owned by insiders.
Large investors have recently made changes to their positions in the business. Valeo Financial Advisors LLC grew its holdings in shares of EXACT Sciences by 154.6% during the 4th quarter. Valeo Financial Advisors LLC now owns 443 shares of the medical research company’s stock valued at $41,000 after acquiring an additional 269 shares in the last quarter. Steward Partners Investment Advisory LLC grew its holdings in shares of EXACT Sciences by 129.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 497 shares of the medical research company’s stock valued at $45,000 after acquiring an additional 280 shares in the last quarter. Shine Investment Advisory Services Inc. grew its holdings in shares of EXACT Sciences by 31.8% during the 3rd quarter. Shine Investment Advisory Services Inc. now owns 518 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 125 shares in the last quarter. Strategic Blueprint LLC purchased a new position in shares of EXACT Sciences during the 3rd quarter valued at $50,000. Finally, Coastal Investment Advisors Inc. grew its holdings in shares of EXACT Sciences by 65.7% during the 3rd quarter. Coastal Investment Advisors Inc. now owns 648 shares of the medical research company’s stock valued at $59,000 after acquiring an additional 257 shares in the last quarter. 87.01% of the stock is currently owned by institutional investors.
About EXACT Sciences
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.
Featured Article: How do investors use RSI to grade stocks?
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.